Results 191 to 200 of about 18,827 (200)

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

Annals of Oncology, 2018
Miguel Martin, Seock-Ah Im, O Lipatov
exaly  

Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer

Annals of Oncology, 2017
Hiroaki Mamiya, M Najafzadeh, S M Tolaney   +2 more
exaly  

A theoretical study of the structure and protonation of Palbociclib (PD 0332991)

Journal of Molecular Structure, 2014
Ibon Alkorta, José Elguero
exaly  

Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies

European Journal of Cancer, 2018
Hope Rugo, Seock-Ah Im, Norikazu Masuda   +2 more
exaly  

Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia–mutated kinase–mediated DNA damage response

European Journal of Cancer, 2018
Cheng-Yi Wang, Kuen-Feng Chen, Chao-Yuan Huang   +2 more
exaly  

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients

Cancer Science, 2016
Kenji Tamura, Yoichi Naito, Hirofumi Mukai   +2 more
exaly  

Palbociclib

Reactions Weekly, 2016
openaire   +1 more source

Selective degradation of CDK6 by a palbociclib based PROTAC

Bioorganic and Medicinal Chemistry Letters, 2019
Amarnath Natarajan, Sandeep Rana, Muhammad Zahid   +2 more
exaly  

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy

Annals of Oncology
José Angel Garcia-Saenz, Catherine M Kelly, Miguel Martin   +2 more
exaly  

Palbociclib

Drugs of the Future, 2013
openaire   +1 more source